"CG Oncology Launches $380M IPO to Lead 2024 Biotech Class"

CG Oncology, a bladder cancer drugmaker, is set to debut on the Nasdaq with a $380 million IPO, marking the first of several biotech IPOs expected before spring. The California company's up-sized listing of 20 million shares priced at $19 per share, giving CG a market value of $1.15 billion.